Antivitamin K drugs in stroke prevention.

Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G.

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused. Current guidelines still regard Vitamin K Antagonists at INR 2·0-3·0 to be the standard treatment after cerebral ischaemia of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effective than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use.
Lingua originaleEnglish
pagine (da-a)817-823
Numero di pagine7
RivistaCurrent Vascular Pharmacology
Volume11
Stato di pubblicazionePublished - 2013

Fingerprint

Vitamin K
Stroke
Pharmaceutical Preparations
Transient Ischemic Attack
Brain Ischemia
Atrial Fibrillation
International Normalized Ratio
Platelet Aggregation Inhibitors
Complementary Therapies
Secondary Prevention
Thrombin
Anticoagulants
Compliance
Cardiac Arrhythmias
Therapeutics
antivitamins K
Guidelines

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cita questo

Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G. (2013). Antivitamin K drugs in stroke prevention. Current Vascular Pharmacology, 11, 817-823.

Antivitamin K drugs in stroke prevention. / Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G.

In: Current Vascular Pharmacology, Vol. 11, 2013, pag. 817-823.

Risultato della ricerca: Article

Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G. 2013, 'Antivitamin K drugs in stroke prevention.', Current Vascular Pharmacology, vol. 11, pagg. 817-823.
Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G. Antivitamin K drugs in stroke prevention. Current Vascular Pharmacology. 2013;11:817-823.
Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G. / Antivitamin K drugs in stroke prevention. In: Current Vascular Pharmacology. 2013 ; Vol. 11. pagg. 817-823.
@article{5e8a2aec155d4a6fbf016843b11d1a73,
title = "Antivitamin K drugs in stroke prevention.",
abstract = "Among the different subtypes of ischaemic strokes, almost 20 {\%} are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused. Current guidelines still regard Vitamin K Antagonists at INR 2·0-3·0 to be the standard treatment after cerebral ischaemia of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effective than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use.",
author = "{Tuttolomondo, A.; Butt{\`a}, C.; Lucifora, B.; Licata, G.} and Antonio Pinto and {Di Raimondo}, Domenico",
year = "2013",
language = "English",
volume = "11",
pages = "817--823",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Antivitamin K drugs in stroke prevention.

AU - Tuttolomondo, A.; Buttà, C.; Lucifora, B.; Licata, G.

AU - Pinto, Antonio

AU - Di Raimondo, Domenico

PY - 2013

Y1 - 2013

N2 - Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused. Current guidelines still regard Vitamin K Antagonists at INR 2·0-3·0 to be the standard treatment after cerebral ischaemia of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effective than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use.

AB - Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused. Current guidelines still regard Vitamin K Antagonists at INR 2·0-3·0 to be the standard treatment after cerebral ischaemia of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effective than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use.

UR - http://hdl.handle.net/10447/97350

M3 - Article

VL - 11

SP - 817

EP - 823

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

ER -